期刊文献+

Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia 被引量:23

Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia
暂未订购
导出
摘要 AIM: To compare the difference of expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia, and to analyze the role of Bcl-2 and Bax proteins in the progression from dysplasia to carcinoma and to evaluate the correlation of Bcl-2/Bax protein expression with the biological behaviors.METHODS: Expressions of Bcl-2 and Bax were examined immunohistochemically in 27 cases of extrahepatic biliary tract carcinomas (bile duct carcinoma: n=21, carcinoma of ampulla of Vater: n=6), and 10 cases of atypical dysplasia.Five cases of normal biliary epithelial tissues were used as controls. A semiquantitative scoring system was used to assess the Bcl-2 and Bax reactivity.RESULTS: The expression of Bd-2 was observed in 10 out of 27 (37.0 %) invasive carcinomas, 1 out of 10 clysplasias, none out of 5 normal epithelial tissues. Bax expression rate was 74.1% (20/27) in invasive carcinoma, 30 % (3/10) in dysplasia,and 40 % (2/5) in normal biliary epithelium. Bcl-2 and Bax activities were more intense in carcinoma than in dysplasia,with no significant difference in Bcl-2 expression (P=0.1:10),and significant difference in Bax expression (P=0.038). Level of Bax expression was higher in invasive carcinoma than in dysplasia and normal tissue (P=0.012). Bcl-2 expression was correlated to Bax expression (P=0.0059). However, Bcl-2/Bax expression had no correlation with histological subtype,grade of differentiation, or level of invasion.CONCLUSION: Increased Bcl-2/Bax expression from dysplasia to invasive tumors supports the view that this is the usual route for the development of extrahepatic biliary tract carcinoma. Bcl-2/Bax may be involved, at least in part,in the apoptotic activity in extrahepatic biliary carcinoma. AIM:To compare the difference of expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia,and to analyze the role of Bcl-2 and Bax proteins in the progression from dysplasia to carcinoma and to evaluate the correlation of Bcl-2/Bax protein expression with the biological behaviors, METHODS:Expressions of Bcl-2 and Bax were examined immunohistochemically in 27 cases of extrahepatic biliary tract carcinomas (bile duct carcinoma:n=21,carcinoma of ampulla of Vater:n=6),and 10 cases of atypical dysplasia. Five cases of normal biliary epithelial tissues were used as controls.A semiquantitative scoring system was used to assess the Bcl-2 and Bax reactivity. RESULTS:The expression of Bcl-2 was observed in 10 out of 27 (37.0 %) invasive carcinomas,1 out of 10 dysplasias,none out of 5 normal epithelial tissues.Bax expression rate was 74.1% (20/27) in invasive carcinoma,30 % (3/10) in dysplasia, and 40 % (2/5) in normal biliary epithelium.Bcl-2 and Bax activities were more intense in carcinoma than in dysplasia, with no significant difference in Bcl-2 expression (P=0.110), and significant difference in Bax expression (P=0.038).Level of Bax expression was higher in invasive carcinoma than in dysplasia and normal tissue (P=0.012).Bcl-2 expression was correlated to Bax expression (P=0.0059).However,Bcl-2/ Bax expression had no correlation with histological subtype, grade of differentiation,or level of invasion. CONCLUSION:Increased Bcl-2/Bax expression from dysplasia to invasive tumors supports the view that this is the usual route for the development of extrahepatic biliary tract carcinoma.Bcl-2/Bax may be involved,at least in part, in the apoptotic activity in extrahepatic biliary carcinoma.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第11期2579-2582,共4页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献30

  • 1[1]Albores-saavedra J, Henson DE, Klimstra DS. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Atlas of tumor pathology, third series, fascicle 27. Washington, DC:Armed Forces Institute of Pathology 2000:181-191
  • 2[2]Yamamoto M, Nakadaira H, Nakamura K. Biliary tract cancer.Gan To Kagaku Ryoho 2001; 28:155-158
  • 3[3]Ichikawa K, Imura J, Kawamata H, Takeda J, Fujimori T. Downregulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. Int J Oncol 2002; 20:453-461
  • 4[4]Niiyama H, Mizumoto K, Kusumoto M, Ogawa T, Suehara N,Shimura H, Tanaka M. Activation of telomerase and its diagnostic application in biopsy specimenes from biliary tract neoplasms.Cancer 1999; 85:2138-2143
  • 5[5]Hoang MP, Murakata LA, Padilla-Rodriguez AL, AlboresSaavedra J. Metaplastic lesions of the extrahepatic bile ducts: a morphologic and immunohistochemical study. Mod Pathol 2001;14:1119-1123
  • 6[6]Adams J, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281:1322-1326
  • 7[7]Kluck RM, Bossy-Wetzed E, Green DR, Newmeyer DD. The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275:1132-1136
  • 8[8]Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275:1129-1132
  • 9[9]Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T,Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608
  • 10[10]Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ.Bad, a heterodimeric parter for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80:285-291

同被引文献99

引证文献23

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部